The company has raised £10mln in a share placing to fund an acceleration of its growth strategy as well as executing “significant commercial opportunities”.
Investor deep dive
Maxcyte fighting cancer battle on two fronts via experimental targeted treatment and technology licensing deals
MaxCyte raises £10mln to extend its CARMA platform into a second trial
Quick facts: MaxCyte
Market Cap: £70.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE